索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]丁国民,沈利水.藻酸盐水凝胶在心力衰竭中的应用现状[J].国际心血管病杂志,2018,03:139-142，145.
点击复制

藻酸盐水凝胶在心力衰竭中的应用现状(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年03期
页码:
139-142，145
栏目:
综述
出版日期:
2018-05-25

文章信息/Info

Title:
-
作者:
丁国民; 沈利水
313300 安吉县人民医院心血管内科(丁国民); 310014 杭州,浙江医院心血管内科(沈利水)
Author(s):
-
关键词:
心力衰竭;  藻酸盐水凝胶;  心室重构;  组织工程
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.03.004
文献标识码:
-
摘要:
慢性心力衰竭(心衰)是多种心血管疾病的终末阶段,可严重影响患者的生活质量及生存率。慢性心衰的发展往往伴随心腔结构的重构、心脏舒缩功能的下降及室壁张力的增高,使得常规药物的治疗效果不尽人意。藻酸盐水凝胶是一种新型生物高分子材料。动物研究发现,注入藻酸盐水凝胶可改善心室壁厚度、心腔内径及室壁应力。Ⅰ期和Ⅱ期临床试验也证实该治疗措施对改善心腔容积、运动耐量及生活质量等方面有一定价值。该文介绍藻酸盐水凝胶近年来的应用现状。
Abstract:
-

参考文献/References

[1] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA)of the ESC.[J]. Eur J Heart Fail, 2016, 18(8):891-975.
[2] Mosterd A, Hoes AW. Clinical epidemiology of heart failure[J]. Heart, 2007, 93(9):1137-1146.
[3] Ponikowski P, Anker SD, Alhabib KF, et al. Heart failure: preventing disease and death worldwide[J]. ESC Heart Failure, 2014, 1(1):4-25.
[4] Gu DF, Huang GY, He J, et al. Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population[J]. Chin J Cardiol, 2003, 31(1):3-6.
[5] 张健, 张宇辉.多中心、前瞻性中国心力衰竭注册登记研究——病因、临床特点和治疗情况初步分析[J]. 中国循环杂志, 2015, 30(5):413-416.
[6] Grodin JL, Tang W. Treatment strategies for the prevention of heart failure[J]. Curr Heart Fail Rep, 2013, 10(4):331-340.
[7] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2):98-122.
[8] Aissaoui N, Morshuis M, Maoulida H, et al. Management of end-stage heart failure patients with or without ventricular assist device:an observational comparison of clinical and economic outcomes[J]. Eur J Cardiothorac Surg, 2018, 53(1):170-177.
[9] Shaddy R, Canter C, Halnon N, et al. Design for the sacubitril/valsartan(LCZ696)compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction(PANORAMA-HF study)[J]. Am Heart J, 2017, 193:23-34.
[10] Feldman T, Mauri L, Kahwash R, et al. Transcatheter InterAtrial shunt device for the treatment of heart failure with preserved ejection fraction(REDUCE LAP-HF Ⅰ): a phase 2, randomized, sham-controlled trial[J]. Circulation, 2018, 137(4):364-375.
[11] Radhakrishnan J, Krishnan UM, Sethuraman S. Hydrogel based injectable scaffolds for cardiac tissue regeneration[J]. Biotechnol Adv, 2014, 32(2):449-461.
[12] Ahmed EM. Hydrogel: preparation, characterization, and applications: a review[J]. J Adv Res, 2015, 6(2):105-121.
[13] Nelson DM, Ma Z, Fujimoto KL, et al. Intra-myocardial biomaterial injection therapy in the treatment of heart failure: materials, outcomes and challenges[J]. Acta Biomater, 2011, 7(1):1-15.
[14] Lee LC, Zhihong Z, Hinson A, et al. Reduction in left ventricular wall stress and improvement in function in failing hearts using Algisyl-LVR[J]. J Vis Exp, 2013, 74:50096.
[15] Leor J, Tuvia S, Guetta V, et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine [J]. J Am Coll Cardiol, 2009, 54(11):1014-1023.
[16] Landa N, Miller L, Feinberg MS, et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat[J]. Circulation, 2008, 117(11):1388-1396.
[17] Sabbah HN, Wang M, Gupta RC, et al. Augmentation of left ventricular wall thickness with alginate hydrogel implants improves left ventricular function and prevents progressive remodeling in dogs with chronic heart failure[J]. JACC Heart Fail, 2013, 1(3):252-258.
[18] Ilsar L, Wang MJ, Sabbah MS, et al. Acute left ventricular reconstruction with circumferential mid-ventricular intramyocardial injections of alginate hydrogel in dogs with chronic heart failure[J]. J Card Fail, 2010, 16(8):S42-S43.
[19] Lee RJ, Hinson A, Helgerson S, et al. Polymer-based restoration of left ventricular mechanics[J]. Cell Transplant, 2013, 22(3):529-533.
[20] Retzlaff B, Voss B, Will A, et al. First in man experience with left ventricular reconstruction in patients with systolic heart failure using a novel approach of biopolymer hydrogel implantation[J]. Circulation, 2010, 122:A19753.
[21] Lee RJ, Hinson A, Bauernschmitt R, et al. The feasibility and safety of Algisyl-LVRTM as a method of left ventricular augmentation in patients with dilated cardiomyopathy: initial first in man clinical results[J]. Int J Cardiol, 2015, 199:18-24.
[22] Anker SD, Coats AJ, Cristian G, et al. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure(AUGMENT-HF trial)[J]. Eur Heart J, 2015, 36(34):2297-2309.
[23] Mann DL, Lee RJ, Coats AJ, et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure[J]. Eur J Heart Fail, 2016, 18(3):314-325.
[24] 刘先宝, 董爱强, 孔敏坚, 等.亚太地区首二例Algisyl可植入性水凝胶治疗心力衰竭[J].中华急诊医学杂志, 2015, 24(6):594-596.
[25] Frey N, Linke A, Süselbeck T, et al. Intracoronary delivery of injectable bioabsorbable scaffold(IK-5001)to treat left ventricular remodeling after ST-elevation myocardial infarction: a first-in-man study[J]. Circ Cardiovasc Interv, 2014, 7(6):806-812.
[26] Rao SV, Zeymer U, Douglas PS, et al. Bioabsorbable intracoronary matrix for prevention of ventricular remodeling after myocardial infarction[J]. J Am Coll Cardiol, 2016, 68(7):715-723.
[27] Pescosolido L, Vermonden T, Malda J, et al. In situ forming IPN hydrogels of Calcium alginate and dextran-HEMA for biomedical applications[J]. Acta Biomater, 2011, 7(4):1627-1633.
[28] Yao X, Liu Y, Gao J, et al. Nitric oxide releasing hydrogel enhances the therapeutic efficacy of mesenchymal stem cells for myocardial infarction[J]. Biomaterials, 2015, 60:130-140.
[29] Boopathy AV, Che PL, Somasuntharam I, et al. The modulation of cardiac progenitor cell function by hydrogel-dependent Notch1 activation[J]. Biomaterials, 2014, 35(28):8103-8112.
[30] Nakajima K, Fujita J, Matsui M, et al. Gelatin hydrogel enhances the engraftment of transplanted cardiomyocytes and angiogenesis to ameliorate cardiac function after myocardial infarction[J]. PLoS One, 2015, 10(7):e0133308.

备注/Memo

备注/Memo:
基金项目:湖州市科技局项目(2014GY36)
通信作者:沈利水,Email:heart0571@163.com
更新日期/Last Update: 2018-06-01